FibroBiologics Inc. (NASDAQ:FBLG) Sees Large Growth in Short Interest

FibroBiologics Inc. (NASDAQ:FBLG) was the target of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 851,743 shares, an increase of 128.4% from the January 15th total of 372,855 shares. Based on an average daily trading volume, of 689,374 shares, the short-interest ratio is currently 1.2 days. Currently, 1.5% of the shares of the company are short sold. Currently, 1.5% of the shares of the company are short sold. Based on an average daily trading volume, of 689,374 shares, the short-interest ratio is currently 1.2 days.

Insider Buying and Selling at FibroBiologics

In other FibroBiologics news, General Counsel Ruben A. Garcia acquired 140,000 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was purchased at an average price of $0.34 per share, with a total value of $47,600.00. Following the transaction, the general counsel directly owned 140,000 shares in the company, valued at approximately $47,600. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 13.00% of the stock is owned by corporate insiders.

Institutional Trading of FibroBiologics

Institutional investors have recently added to or reduced their stakes in the company. Yorkville Advisors Global LP purchased a new position in shares of FibroBiologics during the third quarter valued at approximately $278,000. Landscape Capital Management L.L.C. purchased a new stake in FibroBiologics in the third quarter worth $191,000. Geode Capital Management LLC lifted its position in shares of FibroBiologics by 20.7% during the fourth quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock worth $78,000 after purchasing an additional 59,813 shares during the last quarter. Cascade Financial Partners LLC lifted its position in shares of FibroBiologics by 11.7% during the second quarter. Cascade Financial Partners LLC now owns 290,581 shares of the company’s stock worth $181,000 after purchasing an additional 30,500 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of FibroBiologics by 287.3% in the fourth quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock worth $52,000 after purchasing an additional 171,800 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of FibroBiologics in a research report on Friday, January 2nd. D. Boral Capital reaffirmed a “buy” rating and issued a $15.00 target price on shares of FibroBiologics in a report on Tuesday, January 6th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of FibroBiologics in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $10.00.

FibroBiologics Stock Performance

NASDAQ FBLG traded down $0.01 on Thursday, hitting $0.25. 334,363 shares of the stock were exchanged, compared to its average volume of 1,520,537. FibroBiologics has a 52-week low of $0.22 and a 52-week high of $1.70. The firm has a market capitalization of $16.36 million, a P/E ratio of -0.51 and a beta of -0.60. The stock has a fifty day moving average price of $0.29 and a two-hundred day moving average price of $0.42.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.